ArticleFrontiers in immunology2018
New Vaccine Formulations Containing a Modified Version of the Amastigote 2 Antigen and the Non-Virulent
Article in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 23 citations in OpenAlex.
- Protective Effects of rLPG3 Plus Freund's Incomplete Adjuvant on Parasitism, Hepatic Function, and Immune Modulation in Experimental Visceral Leishmaniasis.ACS infectious diseases · 2026Article
- Characterization of a novelmSphere · 2025Article
- Kharon Is Crucial forPathogens (Basel, Switzerland) · 2025Article
- Advances inPathogens (Basel, Switzerland) · 2024Review
- Review
- Immunogenicity and protective efficacy of tuzin protein as a vaccine candidate inFrontiers in immunology · 2023Article
- Identification of Immunodominant Antigens From a First-Generation Vaccine Against Cutaneous Leishmaniasis.Frontiers in immunology · 2022Article
- Improved Performance of ELISA and Immunochromatographic Tests Using a New Chimeric A2-Based Protein for Human Visceral Leishmaniasis Diagnosis.Journal of immunology research · 2021Observational
- A new multi-epitope peptide vaccine induces immune responses and protection against Leishmania infantum in BALB/c mice.Medical microbiology and immunology · 2020Article
- Evaluation of three recombinant proteins for the development of ELISA and immunochromatographic tests for visceral leishmaniasis serodiagnosis.Memorias do Instituto Oswaldo Cruz · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Visceral leishmaniasis (VL) is a major public health issue reported as the second illness in mortality among all tropical diseases. Clinical trials have shown that protection against VL is associated with robust T cell responses, especially those producing IFN-γ. The
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.